SMS Pharmaceuticals Ltd (SMSPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 517655,
    "name": "SMS Pharma.",
    "stock_name": "SMS Pharma.",
    "full_name": "SMS Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sms-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "315.00",
    "chg": -1.55,
    "chgp": "-0.49%",
    "dir": -1,
    "prev_price": "316.55",
    "mcapval": "2,950.04 Cr",
    "mcap": "Small Cap",
    "scripcode": 532815,
    "symbol": "SMSPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE812G01025",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.8 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/sms-pharma-517655-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "SMS Pharma Sees Revision in Market Assessment Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sms-pharma-upgraded-from-sell-to-hold-by-marketsmojo-on-1-sep-2025-3736976",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharma_mojoScore_3736976.png",
        "date": "2025-11-29 17:52:00",
        "description": "SMS Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a shift in analytical perspective. This adjustment follows recent financial disclosures and market performance, highlighting a complex interplay of operational metrics and valuation considerations."
      },
      {
        "title": "SMS Pharmaceuticals Hits New 52-Week High at Rs.335.25",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-hits-new-52-week-high-at-rs33525-3733082",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_priceRelatedfactors_3733082.png",
        "date": "2025-11-27 09:53:18",
        "description": "SMS Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.335.25, marking a notable phase of momentum in the Pharmaceuticals & Biotechnology sector. This achievement reflects the stock’s sustained upward trajectory over recent sessions."
      },
      {
        "title": "SMS Pharmaceuticals Hits New 52-Week High at Rs.335.25",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-hits-new-52-week-high-at-rs33525-3733079",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_priceRelatedfactors_3733079.png",
        "date": "2025-11-27 09:53:17",
        "description": "SMS Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.335.25, reflecting sustained momentum in the Pharmaceuticals & Biotechnology sector amid a broadly positive market environment."
      },
      {
        "title": "Is SMS Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sms-pharma-overvalued-or-undervalued-3732482",
        "imagepath": "",
        "date": "2025-11-27 08:25:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Premium Pricing</strong></p>\n<p>As of 26 Nov 2025, SMS Pharma’s price-to-earnings (PE) ratio stands at 35.8, significantly higher than the broader market average and many of its pharmaceutical peers. This elevated PE ratio signals that investors are willing to pay a substantial premium for the company’s earnings, reflecting expectations of sustained growth or superior profitability. The price-to-book (P/B) ratio of 4.14 further underscores the premium valuation, indicating that the stock is priced well above its net asset value.</p>\n<p>Enterprise value multiples also point to an expensive valuation. The EV to EBIT ratio of 26.0 and EV to EBITDA of 20.1 are notably higher than several competitors, suggesting that the market values SMS Pharma’s operating earnings mor..."
      },
      {
        "title": "SMS Pharmaceuticals Shows Strong Momentum Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-surges-on-bullish-technical-momentum-amid-sector-outperformance-3732400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_technicaldot_3732400.png",
        "date": "2025-11-27 08:03:26",
        "description": "SMS Pharmaceuticals has exhibited notable price momentum in recent weeks, reflecting a shift in technical indicators that suggest a more bullish outlook. The stock’s performance contrasts favourably with broader market benchmarks, supported by a combination of moving averages, MACD, and Bollinger Bands signals that point to sustained upward pressure."
      },
      {
        "title": "Why is SMS Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sms-pharma-fallingrising-3732054",
        "imagepath": "",
        "date": "2025-11-27 00:26:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Price Momentum and Market Outperformance</strong></p>\n<p>SMS Pharmaceuticals has demonstrated remarkable price momentum in recent trading sessions. The stock has gained 13.99% over the past week, vastly outperforming the Sensex’s modest 0.50% rise during the same period. Over the last month, SMS Pharma. has appreciated by 8.13%, compared to the Sensex’s 1.66%, while year-to-date returns stand at an impressive 34.50%, significantly ahead of the benchmark’s 9.56%. This trend extends over longer horizons, with the stock delivering 21.80% returns in the last year against the Sensex’s 7.01%, and an extraordinary 281.10% gain over three years, dwarfing the benchmark’s 37.43%.</p>\n<p>On 26-Nov, the stock traded close to its 52-week high, just 1.98% shy of the peak price of ₹329. It touched a..."
      },
      {
        "title": "SMS Pharmaceuticals Hits Intraday High with Strong 7.4% Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-hits-intraday-high-with-741-surge-on-26-nov-2025-3731128",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_priceRelatedfactors_3731128.png",
        "date": "2025-11-26 10:21:09",
        "description": "SMS Pharmaceuticals recorded a robust intraday performance on 26 Nov 2025, touching a day’s high of Rs 297.25, reflecting a 7.41% gain. The stock outpaced its sector and broader market indices, supported by sustained buying momentum and favourable technical indicators."
      },
      {
        "title": "SMS Pharmaceuticals Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-technical-momentum-shifts-amid-mixed-indicator-signals-3723687",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_technicaldot_3723687.png",
        "date": "2025-11-24 08:02:35",
        "description": "SMS Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Recent evaluation adjustments highlight a transition from a strongly bullish trend to a more mildly bullish stance, underscoring the evolving market dynamics within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "SMS Pharmaceuticals Hits New 52-Week High of Rs. 329 Amid Strong Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-hits-new-52-week-high-of-rs-329-amid-strong-momentum-3685242",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SMSPharmaceutic_priceRelatedfactors_3685242.png",
        "date": "2025-11-10 10:38:33",
        "description": "SMS Pharmaceuticals achieved a new 52-week high of Rs. 329 on November 10, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has gained 13.61% over three days and is trading above key moving averages, indicating a robust upward trend amid positive broader market sentiment."
      }
    ],
    "total": 698,
    "sid": "517655",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/sms-pharmaceuticals-517655"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 31St December 2025",
      "datetime": "31-Jan-2026",
      "details": "SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve the Unaudited (Standalone and Consolidated) Financial Results of the Company for the third quarter ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Report On Transfer Requests Of Physical Shares Re-Lodged Under The Special Window",
      "datetime": "17-Jan-2026",
      "details": "Please find enclosed.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Certificate under 74(5) of SEBI(DP) Regulations for the quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "SMS Pharmaceuticals Ltd has declared <strong>40%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "SMS Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 17 Dec 15",
          "dt": "2015-12-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

SMS Pharma Sees Revision in Market Assessment Amidst Mixed Financial Signals

2025-11-29 17:52:00

SMS Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a shift in analytical perspective. This adjustment follows recent financial disclosures and market performance, highlighting a complex interplay of operational metrics and valuation considerations.

SMS Pharmaceuticals Hits New 52-Week High at Rs.335.25

2025-11-27 09:53:18

SMS Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.335.25, marking a notable phase of momentum in the Pharmaceuticals & Biotechnology sector. This achievement reflects the stock’s sustained upward trajectory over recent sessions.

SMS Pharmaceuticals Hits New 52-Week High at Rs.335.25

2025-11-27 09:53:17

SMS Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.335.25, reflecting sustained momentum in the Pharmaceuticals & Biotechnology sector amid a broadly positive market environment.

Is SMS Pharma. overvalued or undervalued?

2025-11-27 08:25:07

Valuation Metrics Indicate Premium Pricing As of 26 Nov 2025, SMS Pharma’s price-to-earnings (PE) ratio stands at 35.8, significantly higher than the broader market average and many of its pharmaceutical peers. This elevated PE ratio signals that investors are willing to pay a substantial premium for the company’s earnings, reflecting expectations of sustained growth or superior profitability. The price-to-book (P/B) ratio of 4.14 further underscores the premium valuation, indicating that the stock is priced well above its net asset value. Enterprise value multiples also point to an expensive valuation. The EV to EBIT ratio of 26.0 and EV to EBITDA of 20.1 are notably higher than several competitors, suggesting that the market values SMS Pharma’s operating earnings mor...

SMS Pharmaceuticals Shows Strong Momentum Amid Technical Shifts

2025-11-27 08:03:26

SMS Pharmaceuticals has exhibited notable price momentum in recent weeks, reflecting a shift in technical indicators that suggest a more bullish outlook. The stock’s performance contrasts favourably with broader market benchmarks, supported by a combination of moving averages, MACD, and Bollinger Bands signals that point to sustained upward pressure.

Why is SMS Pharma. falling/rising?

2025-11-27 00:26:26

Strong Price Momentum and Market Outperformance SMS Pharmaceuticals has demonstrated remarkable price momentum in recent trading sessions. The stock has gained 13.99% over the past week, vastly outperforming the Sensex’s modest 0.50% rise during the same period. Over the last month, SMS Pharma. has appreciated by 8.13%, compared to the Sensex’s 1.66%, while year-to-date returns stand at an impressive 34.50%, significantly ahead of the benchmark’s 9.56%. This trend extends over longer horizons, with the stock delivering 21.80% returns in the last year against the Sensex’s 7.01%, and an extraordinary 281.10% gain over three years, dwarfing the benchmark’s 37.43%. On 26-Nov, the stock traded close to its 52-week high, just 1.98% shy of the peak price of ₹329. It touched a...

SMS Pharmaceuticals Hits Intraday High with Strong 7.4% Surge

2025-11-26 10:21:09

SMS Pharmaceuticals recorded a robust intraday performance on 26 Nov 2025, touching a day’s high of Rs 297.25, reflecting a 7.41% gain. The stock outpaced its sector and broader market indices, supported by sustained buying momentum and favourable technical indicators.

SMS Pharmaceuticals Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-24 08:02:35

SMS Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Recent evaluation adjustments highlight a transition from a strongly bullish trend to a more mildly bullish stance, underscoring the evolving market dynamics within the Pharmaceuticals & Biotechnology sector.

SMS Pharmaceuticals Hits New 52-Week High of Rs. 329 Amid Strong Momentum

2025-11-10 10:38:33

SMS Pharmaceuticals achieved a new 52-week high of Rs. 329 on November 10, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has gained 13.61% over three days and is trading above key moving averages, indicating a robust upward trend amid positive broader market sentiment.

View All News